Synspira
Boston
Massachusetts
United States
Tel: 781-235-3060
Website: http://www.synspira.com/
Email: info@synspira.com
About Synspira
Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform for the development of inhaled glycopolymer-based therapeutics in pulmonary indications. Synspira is using proprietary modified polysaccharide molecules to disrupt bacterial biofilms and to help expectorate mucus, exposing otherwise protected bacteria to antibiotics. This new approach to the treatment of disease pathology has the potential to improve pulmonary function and reduce antibiotic resistance in a number of infectious diseases.YEAR FOUNDED:
2017
LEADERSHIP:
CEO: Shenda Baker, Ph.D.
CFO: Kim Snyder, MBA
CMO: Gregory Fiore MD
PIPELINE:
Please click here for Synspira's pipeline.
9 articles about Synspira
-
CF Foundation Commits up to $14 Million in Funding to Expand Research Agreement With Synspira Therapeutics
10/20/2020
Today, the Cystic Fibrosis Foundation announced it is expanding its research collaboration with Synspira Therapeutics Inc., committing up to $14 million in additional funding to develop a non-porcine enzyme replacement therapy and a novel treatment to help fight drug-resistant infections. The new fun
-
Synspira Therapeutics Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union
4/10/2019
Synspira received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for SNSP113 in October 2018
-
Synspira Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference
10/12/2018
Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that three abstracts have been accepted for presentation at the 32nd Annual North American Cystic Fibrosis Conference (
-
Synspira Receives U.S. FDA Orphan Designation for PAAG15A for the Treatment of Cystic Fibrosis
10/11/2018
Synspira is developing PAAG15A as SNSP113, a potential inhaled treatment to improve lung function in patients with cystic fibrosis
-
Synspira’s PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells
8/9/2018
Results published in Frontiers in Microbiology-Antimicrobials, Resistance and Chemotherapy
-
Synspira’s Novel Glycopolymer Proves Effective Against Antibiotic Resistance
1/18/2018
Synspira today announced the results of a study exploring poly-N (acetyl, arginyl) glucosamine (PAAG) as a potential new treatment for methicillin-resistant Staphylococcus aureus (MRSA).
-
Synspira Announces $3 Million Development Award From Cystic Fibrosis Foundation
1/3/2018
Synspira today announced that it has received up to a $3 million award from the Cystic Fibrosis (CF) Foundation to advance clinical development of its lead candidate, SNSP113, for use in pulmonary complications of cystic fibrosis (CF).
-
Synspira Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference
11/2/2017
The studies were led by the laboratory of Steven M. Rowe M.D. at the University of Alabama at Birmingham and will be presented at the 31st Annual North American Cystic Fibrosis Conference (NACFC), being held from November 2-4, 2017 in Indianapolis, IN.
-
Synspira Announces First Patient Dosed In Phase 1a Study Of SNSP113 In Cystic Fibrosis
10/19/2017
Synspir announced initiation of a Phase 1a first-in-human, multi-center study of SNSP113, its lead drug candidate, in development for use in pulmonary complications of cystic fibrosis (CF).